Efficacy of Mogamulizumab by Prior Systemic Therapy in Patients With Previously Treated Cutaneous T-Cell Lymphoma: Post Hoc Analysis From the Phase 3 MAVORIC Study

被引：0
作者：
Scarisbrick, J. [1 ]
Zinzani, P. L. [2 ]
Horwitz, S. [3 ]
Kim, Y. H. [4 ]
Moskowitz, A. J. [3 ]
Porcu, P. [5 ]
Leoni, M. [6 ]
Dwyer, K. [6 ]
Sun, W. [6 ]
Nikonova, E. [7 ]
Bagot, M. [8 ]
机构：
[1] Univ Hosp Birmingham, Birmingham, W Midlands, England
[2] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Stanford Univ, Stanford, CA 94305 USA
[5] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[6] Kyowa Kirin Pharmaceut Dev Inc, Princeton, NJ USA
[7] Kyowa Kirin Inc, Bedminster, NJ USA
[8] Univ Paris 07, Inserm U976, Hop St Louis, AP HP, Paris, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷
关键词：
Cutaneous T-cell Lymphoma; Mogamulizumab; Mycosis Fungoides; Sezary syndrome;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH19-PO-0
引用
收藏
页码：94 / 94
页数：1
相关论文
共 43 条
  • [41] Disease site as a determinant of survival outcome in patients with primary cutaneous peripheral T-cell lymphoma, unspecified: an analysis of 4057 cases from the US National Cancer Database
    Su, Chang
    Nguyen, Kevin A.
    Bai, Harrison X.
    Cao, Ya
    Tao, Yongguang
    Karakousis, Giorgos
    Zhang, Paul J.
    Zhang, Guiying
    Xiao, Rong
    LEUKEMIA & LYMPHOMA, 2018, 59 (09) : 2105 - 2112
  • [42] Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy
    Sato, Tomoo
    Nagai, Masahiro
    Watanabe, Osamu
    Misu, Tatsuro
    Takenouchi, Norihiro
    Ohkubo, Ryuichi
    Ishihara, Satoshi
    Tsuboi, Yoshio
    Katsuno, Masahisa
    Nakagawa, Masanori
    Matsushita, Takuya
    Aso, Yasuhiro
    Matsuura, Eiji
    Tokashiki, Takashi
    Mukaino, Akihiro
    Adachi, Hiroaki
    Nakanishi, Kaoru
    Yamaguchi, Yusuke
    Yamaguchi, Saaya
    Yamano, Yoshihisa
    JOURNAL OF NEUROLOGY, 2024, 271 (06) : 3471 - 3485
  • [43] IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
    Bagot, Martine
    Porcu, Pierluigi
    Marie-Cardine, Anne
    Battistella, Maxime
    William, Basem M.
    Vermeer, Maarten
    Whittaker, Sean
    Rotolo, Federico
    Ram-Wolff, Caroline
    Khodadoust, Michael S.
    Bensussan, Armand
    Paturel, Carine
    Bonnafous, Cecile
    Sicard, Helene
    Azim, Hatem A., Jr.
    Kim, Youn H.
    LANCET ONCOLOGY, 2019, 20 (08) : 1160 - 1170
12345